<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010683</url>
  </required_header>
  <id_info>
    <org_study_id>GLP1-DM-ATTIKON</org_study_id>
    <nct_id>NCT03010683</nct_id>
  </id_info>
  <brief_title>Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus</brief_title>
  <official_title>Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover,&#xD;
      the integrity of endothelial glycocalyx plays a vital role in vascular permeability,&#xD;
      inflammation and elasticity. Agonists of Glucagon like peptide - 1 receptors (GLP-1R) used in&#xD;
      the treatment of type 2 diabetes mellitus (T2DM). This category includes exenatide and&#xD;
      liraglutide. These drugs lower glucose levels by inhibiting the secretion of glucagon,&#xD;
      promoting the release of insulin in response to hyperglycemia, slowing gastric emptying, and&#xD;
      augmenting satiety. Clinical studies have shown that GLP-1R agonists have beneficial effects&#xD;
      on cardiovascular function in both diabetic patients and healthy subjects. The purpose of&#xD;
      this study is to investigate in patients with T2DM without coronary artery disease (CAD),&#xD;
      patients with T2DM and CAD and obese patients with abnormal oral glucose tolerance test&#xD;
      (OGTT), changes in arterial stiffness, endothelial glycocalyx thickness and coronary reserve&#xD;
      flow (CFR) after treatment with metformin or agonist GLP-1R.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study three groups matched for age and sex: 30 patients with type 2&#xD;
      diabetes mellitus (T2DM) without coronary artery disease (CAD), 30 patients with T2DM and CAD&#xD;
      and 30 obese patients (BMI &gt;30 Kg/m²) with abnormal oral glucose tolerance test (OGTT). It&#xD;
      will be a randomized study with metformin or GLP-1R agonist treatment for 1 year. All&#xD;
      subjects will receive for 1 year: (a) GLP-1R agonist or (b) metformin. At 0, 3, 6 and 12&#xD;
      months, where 0 is the starting point of treatment, blood samples will be collected.&#xD;
&#xD;
      At 0, 3, 6 and 12 months the investigators will measure:&#xD;
&#xD;
        1. Carotid-femoral pulse wave velocity (PWV, m/sec) using tonometry by Complior (SP ALAM)&#xD;
           and augmentation index (AI, %) by the method of arteriography (Arteriograph, TensioMed)&#xD;
&#xD;
        2. Perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels&#xD;
           (ranged from 5-25 micrometers) using Sideview Darkfield imaging (Microscan, Glycocheck).&#xD;
           Increased PBR is considered an accurate non invasive index of reduced endothelial&#xD;
           glucocalyx thickness.&#xD;
&#xD;
        3. Coronary flow reserve (CFR) in the left anterior descending artery after infusion of&#xD;
           adenosine using Doppler echocardiography.&#xD;
&#xD;
        4. Determination of the following parameters in blood: glucose, insulin, free fatty acids,&#xD;
           triglycerides, glycerol, C reactive protein (CRP), transforming growth factor-b (TGF-b),&#xD;
           Lipoprotein-Associated Phospholipase A2 (LP-LPA2), tumor necrosis factor-a (TNF-a),&#xD;
           interleukins 6 and 10 (IL6 and IL10), propeptide of type I procollagen (PIP), propeptide&#xD;
           of procollagen type III (PIIINP), matrix metallopeptidases 9 and 2 (MMP),&#xD;
           macrophage-colony stimulating factor (MCSF), growth differentiation factor-15 (GDF-15),&#xD;
           N-terminal pro b-type natriuretic peptide (NT-proBNP) and galectin-3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</measure>
    <time_frame>Baseline, 3 months, 6 months and 12 months</time_frame>
    <description>Differences in carotid-femoral pulse wave velocity (PWV, m/sec) using tonometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
    <description>Differences in augmentation index (AI, %) using oscillometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in Coronary Flow Reserve at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
    <description>Differences in coronary flow reserve (CFR) using Doppler echocardiography at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
    <description>Differences in endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. High PBR values represent reduced glycocalyx thickness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Glycocalyx and Pulse Wave Velocity.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
    <description>Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with pulse wave velocity (PWV, m/sec) at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Glycocalyx and Coronary Flow Reserve.</measure>
    <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
    <description>Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with coronary flow reserve (CFR) using Doppler echocardiography at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection</description>
    <arm_group_label>liraglutide</arm_group_label>
    <other_name>Victoza (liraglutide)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage (Metformin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus (T2DM) without coronary artery disease (CAD)&#xD;
&#xD;
          -  Patients with T2DM and CAD.&#xD;
&#xD;
          -  Obese patients (BMI &gt;30 Kg/m²) with abnormal oral glucose tolerance test (OGTT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  valvular heart disease&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  peripheral vascular disease&#xD;
&#xD;
          -  liver or kidney failure&#xD;
&#xD;
          -  history of alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignatios Ikonomidis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Cardiology Department, University of Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Pavlidis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Cardiology Department, University of Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vaia Lambadiari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Department of Internal Medicine, University of Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fotini Kousathana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Department of Internal Medicine, University of Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Dimitriadis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Department of Internal Medicine, University of Athens, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Lekakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Cardiology Department, University of Athens, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>''Attikon'' University General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>March 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Ignatios Ikonomidis</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Arterial stiffness</keyword>
  <keyword>Endothelial glycocalyx</keyword>
  <keyword>Coronary flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03010683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide</title>
          <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide</title>
          <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse Wave Velocity</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="2.5"/>
                    <measurement group_id="B2" value="11.2" spread="3"/>
                    <measurement group_id="B3" value="11.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
        <description>Differences in carotid-femoral pulse wave velocity (PWV, m/sec) using tonometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
        <time_frame>Baseline, 3 months, 6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
          <description>Differences in carotid-femoral pulse wave velocity (PWV, m/sec) using tonometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="2.5"/>
                    <measurement group_id="O2" value="11.2" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="2.8"/>
                    <measurement group_id="O2" value="11.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="3.3"/>
                    <measurement group_id="O2" value="11" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="1.9"/>
                    <measurement group_id="O2" value="10.8" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
        <description>Differences in augmentation index (AI, %) using oscillometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
        <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Augmentation Index at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
          <description>Differences in augmentation index (AI, %) using oscillometry at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
          <units>percentage of the central pulse pressure</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="-1" upper_limit="31"/>
                    <measurement group_id="O2" value="14" lower_limit="-9" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="-2" upper_limit="29"/>
                    <measurement group_id="O2" value="13.6" lower_limit="-6" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="-2" upper_limit="31"/>
                    <measurement group_id="O2" value="15" lower_limit="-8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="-1" upper_limit="32"/>
                    <measurement group_id="O2" value="15.3" lower_limit="-6" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differences in Coronary Flow Reserve at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
        <description>Differences in coronary flow reserve (CFR) using Doppler echocardiography at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
        <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
        <population>The investigators did not measure coronary flow reserve (CFR).</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Coronary Flow Reserve at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
          <description>Differences in coronary flow reserve (CFR) using Doppler echocardiography at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
          <population>The investigators did not measure coronary flow reserve (CFR).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
        <description>Differences in endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. High PBR values represent reduced glycocalyx thickness.</description>
        <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.</title>
          <description>Differences in endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R. High PBR values represent reduced glycocalyx thickness.</description>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.29"/>
                    <measurement group_id="O2" value="2.13" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.3"/>
                    <measurement group_id="O2" value="2.15" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.2"/>
                    <measurement group_id="O2" value="2.13" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.2"/>
                    <measurement group_id="O2" value="2.10" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Glycocalyx and Pulse Wave Velocity.</title>
        <description>Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with pulse wave velocity (PWV, m/sec) at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
        <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Glycocalyx and Pulse Wave Velocity.</title>
          <description>Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with pulse wave velocity (PWV, m/sec) at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
          <units>Pearson correlation coefficient (r)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39"/>
                    <measurement group_id="O2" value="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36"/>
                    <measurement group_id="O2" value="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32"/>
                    <measurement group_id="O2" value="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44"/>
                    <measurement group_id="O2" value="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Glycocalyx and Coronary Flow Reserve.</title>
        <description>Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with coronary flow reserve (CFR) using Doppler echocardiography at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
        <time_frame>Baseline, 3 months, 6 months, and 12 months.</time_frame>
        <population>The investigators did not estimate the association between endothelial glycocalyx thickness and coronary flow reserve (CFR) because they did not measure the CFR.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Glycocalyx and Coronary Flow Reserve.</title>
          <description>Association of endothelial glycocalyx thickness as assessed by perfused boundary region (PBR, micrometers) of the sublingual arterial microvessels with coronary flow reserve (CFR) using Doppler echocardiography at baseline and 3, 6 and 12 months after treatment with metformin or agonist GLP-1R.</description>
          <population>The investigators did not estimate the association between endothelial glycocalyx thickness and coronary flow reserve (CFR) because they did not measure the CFR.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide</title>
          <description>Stimulation of glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8 mg once daily as a subcutaneous injection</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>Antidiabetic drug - biguanide class (Glucophage) 1000 mg twice daily per os</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Οur study has a modest number of subjects. Additional large scale studies are needed to expand our results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Ignatios Ikonomidis</name_or_title>
      <organization>2nd Cardiology Department, National and Kapodistrian University of Athens, Attikon Hospital</organization>
      <phone>+30 6944805732</phone>
      <email>ignoik@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

